A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®. Telix Pharmaceuticals has submitted a Biologics License ...
Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback